Oncology Views & Analysis

Views & Analysis

Oncology

With over 8,200 abstracts accepted, ASH 2025 showcased breakthroughs in sickle cell disease, platelet disorders, and next-generation cell therapies.

Oncology

Andrew Newland, former CEO of ANGLE, explains why live cell liquid biopsies should become standard in oncology.

Oncology

Perspective Therapeutics is advancing image‑guided, targeted alpha‑particle therapies (TATs). We spoke to Thijs Spoor at ESMO 2025 to find out more.

Oncology

Craig Eagle, chief medical officer of Guardant Health, discusses blood as a rich source of biomarker development in cancer prognosis.

Oncology

Molecular recycling could transform the economics and innovation of oncology drug discovery.

Oncology

ESMO 2025 reflected a field in the midst of rapid evolution – one that is increasingly defined by personalisation and data-driven decision-making.